The X protein of Borna disease virus (BDV) negatively regulates viral polymerase activity. With a BDV mini-replicon system, 30 % inhibition of polymerase activity was observed at an X to phosphoprotein (P) plasmid ratio of 1 : 6 and 100 % inhibition at a ratio of 1 : 1. It was therefore hypothesized that (i) the X : P ratio in infected cells is not significantly higher than 1 : 6 to prevent complete inhibition of polymerase activity and (ii) X is not efficiently incorporated into viral particles, allowing efficient replication early in infection. To test these assumptions, a monoclonal antibody directed against BDV X was generated. Immunofluorescence analysis revealed co-localization of X with the nucleoprotein (N) and P in the nucleus, as well as in the cytoplasm of BDV-infected cells. Quantification of viral protein levels by Western blot analysis, using purified Escherichia coli-derived X, P and N as protein standards, revealed an X : P : N ratio in BDV-infected cells of approximately 1 : 6 : 40. However, only traces of X could be detected in purified BDV stock, suggesting that X is excluded from virus particles. These results indicate that X is a non-structural protein. The lack of X in virus particles may facilitate polymerase activity early in infection; however, the presence of X in persistently infected cells may result in partial inhibition of the polymerase and thus contribute to viral persistence.
INTRODUCTION
Borna disease virus (BDV) is a non-segmented, negativestrand RNA virus that replicates in the central nervous system of a broad range of warm-blooded animals (Ludwig et al., 1988; Staeheli et al., 2000) . Natural and experimental infections with BDV usually result in immune system-mediated neurological diseases including behavioural abnormalities (Hornig et al., 2003; Pletnikov et al., 2002) . BDV infection is potentially linked to human psychiatric diseases, as BDV-specific antibodies were identified in sera of psychiatric patients with higher prevalence than in control cohorts (Jordan & Lipkin, 2001; Planz et al., 2002) . Attempts to confirm human BDV infection by non-serological methods, such as detection of viral nucleic acid by nested RT-PCR or virus isolation, have given inconsistent results and therefore this issue remains controversial (Jordan & Lipkin, 2001; Planz et al., 2002) .
In contrast to other members of the Mononegavirales, BDV replicates in the nucleus of infected cells and uses the splicing machinery for maturation of viral transcripts (Briese et al., 1992; Cubitt et al., 1994; Schneider et al., 1994) . It encodes at least six viral proteins: the nucleoprotein (N), negative regulator (X), phosphoprotein (P), matrix protein (M), glycoprotein (G) and polymerase (L) (Briese et al., 1994) . Whereas M and G are involved in particle formation, protein-binding studies suggest that P, N, L and X constitute the polymerase complex. P forms homooligomers and can act as a scaffold protein for polymerase complex formation Schwemmle et al., 1998; Wolff et al., 2000) . The interaction domain for X is localized to the N-terminal half of P, whereas the oligomerization and L-and N-binding domains are found in the C-terminal half of P Schwemmle et al., 1998; Wolff et al., 2000) . Data from a BDV-specific mini-replicon system has challenged the view that X is essential to reconstitute an active polymerase complex, since N, P and L alone were sufficient to achieve replication and transcription (Perez et al., 2003; Schneider et al., 2003) . Furthermore, additional expression of X resulted in a pronounced inhibition of polymerase activity (Perez et al., 2003; Schneider et al., 2003) and thus identified this protein as a negative regulator of the polymerase.
The precise mechanism by which X regulates viral polymerase activity is unclear. It is believed that complex formation between X and P prevents the formation of an active polymerase complex in the nucleus. This hypothesis is based on the observation that co-expression of X and P partially results in cytoplasmic accumulation of both proteins (Kobayashi et al., 2003; Poenisch et al., 2004) . A cytoplasmic localization of X-P complexes is also frequently observed in Madin-Darby canine kidney (MDCK) cells persistently infected with BDV (Kobayashi et al., 2003) , supporting this hypothesis. Furthermore, P is only found in the nucleus of BDV-infected MDCK cells that lack detectable expression of X (Kobayashi et al., 2003) . However, others found a co-localization of X and P in the nucleus of C6 cells persistently infected with BDV (Schwemmle et al., 1998) , suggesting that the cytoplasmic retention of P by X is most likely not the only mechanism by which X regulates the polymerase activity. Recent observations that P multimers can bind simultaneously to X and L suggest that ribonucleoprotein (RNP)-bound X could modulate the viral polymerase activity in the nucleus as well.
Data from the BDV mini-replicon assay has revealed that BDV-X can inhibit polymerase activity by 30 % at X : P plasmid ratios of 1 : 6 and almost completely when equimolar amounts are used (Schneider et al., 2003) . We therefore hypothesized that the X : P protein ratio is low in persistently infected cells to maintain virus replication and that X is not efficiently incorporated into viral particles, allowing efficient polymerase activity early after infection. To determine unequivocally the subcellular localization and expression levels of X in infected cells, we generated a monoclonal antibody (mAb) against this protein. mAb 10/1G3 specifically recognized a linear epitope of X (   70   PLHDLRPRP   78 ) and revealed a co-localization of X with P and N in the nucleus and cytoplasm of BDV-infected cells. Based on Western blot analysis, the ratio of X : P : N in crude cell extract was found to be 1 : 6 : 40. Only traces of X were found in concentrated virus stocks, corresponding to an X : P ratio of ¡1 : 330. Thus, the X protein represents a non-structural protein and cannot interfere with virus replication steps early in infection, whereas the level of X in persistently infected cells is most likely sufficient to exert partial inhibition of the polymerase activity. We propose that X regulates the activity of P directly in the nucleus and not solely by retranslocation into the cytoplasm.
METHODS
Generation of antibodies. To generate a mAb directed against the X protein, female BALB/c mice were immunized intraperitoneally (i.p.) with 20 mg recombinant GST-X protein diluted in 200 ml 50 % complete Freund's adjuvant in PBS (Sigma). After 2 and 4 weeks, the mice received a second and third i.p. injection of 20 mg recombinant GST-X diluted in 200 ml 50 % incomplete Freund's adjuvant in PBS (Sigma). Six weeks after the initial i.p. immunization, mice were boosted intravenously with 20 mg maltose binding protein (MBP)-X fusion protein diluted in 100 ml PBS. Four days later, the spleen was taken and fused with the mouse myeloma cell line X63-Ag8.653 (Kearney et al., 1979) . Two weeks later, supernatants of hybridomas were tested in Western blot analyses for reactivity against recombinant His-tagged X protein and extract from BDV-infected human oligodendrocyte (Oligo) cells. Hybridomas producing reactive supernatant were expanded and cells were frozen at 280 uC for further analysis. Hybridoma 10/1G3 was subcloned three times to ensure a clonal origin. Antibody is available on request from O. Planz (Friedrich Loeffler-Institut, Tübingen, Germany).
To generate an M-specific antibody, New Zealand white rabbits were immunized subcutaneously (s.c.) with 200 mg peptide-KLH (M35; N 2 H-NQFLNIPFLSV-COOH) in complete Freund's adjuvant (Sigma). After 3, 6 and 9 weeks, the rabbits received a second, third and fourth s.c. injection of 200 mg peptide-KLH in incomplete Freund's adjuvant (Sigma). Twelve weeks after the initial immunization, blood was taken from the rabbits. The specificity of this antibody was verified by Western blot analysis (data not shown).
Plasmids. pET15b-based expression plasmids (Novagen) encoding His-tagged BDV N (pHis-N) and P (pHis-P) have been described previously (Schwemmle et al., 1997 (Schwemmle et al., , 1998 . To generate a His-tagged X expression plasmid (pHis-X), the complete ORF of X (BDV strain He/80) was amplified from plasmid pTRE-X (Schwemmle et al., 1998) and cloned into the NdeI/BamHI restriction sites of pET15b. In a second step, nucleotide exchanges ( 49 AAT 51 to 49 GCG 51 ) were introduced by PCR mutagenesis as described by the manufacturer (Invitrogen). The nucleotide exchanges resulted in a single amino acid substitution of the X protein (N17A). The bacterial expression plasmid pMAL-X encoding an MBP-X fusion protein was constructed by inserting BDV X from pGEX-p10 Schwemmle et al., 1998; Wolff et al., 2000) cDNA into pMAL-c2 (New England Biolabs).
Protein preparation. Purification of His-tagged proteins from Escherichia coli was carried out as described previously (Schwemmle et al., 1997) . Briefly, cells were suspended in 50 mM Tris/HCl, pH 8?0, 5 mM MgCl 2 , 500 mM NaCl, 10 % glycerol, 20 mM imidazole and 200 mM Pefabloc (Roth), disrupted by sonication, bound to a Ni-NTA agarose column (Qiagen) and stepwise eluted with 20 mM Tris/HCl, pH 8?0, 5 mM MgCl 2 , 100 mM NaCl, 10 % glycerol and 500 mM imidazole. Fractions containing His-tagged viral proteins were pooled and stored at 280 uC. The purity of the Histagged proteins was >95 % as judged by Coomassie blue staining. MBP-X fusion protein was purified from bacterial lysates by affinity chromatography on an amylose resin (New England Biolabs) following the instructions of the manufacturer.
Western blot analysis and quantification of protein levels.
BDV-infected or uninfected cells were pooled and lysed in gel loading buffer (Laemmli & Favre, 1973) , followed by ultrasonication. Protein extracts were size fractionated by 15 % SDS-PAGE and blotted on to a PVDF membrane (Millipore) for Western blot analysis. The membrane was blocked with milk powder (2 %, w/v, in PBS) for 2 h and then incubated with the indicated antibodies in PBS containing 0?2 % milk powder (w/v) overnight. After intense washing in PBS containing 0?1 % Tween 20 (Sigma), the blot was incubated with a 1 : 2000 dilution of a peroxidase-coupled donkey anti-mouse or anti-rabbit polyclonal antiserum (Dianova) for 1 h at room temperature. Finally, bound enzymic activity was detected using the enhanced chemiluminescence system (ECL+) from Amersham. Signal intensities of the virus-encoded proteins and the known amounts of the E. coli-purified His-tagged marker proteins were determined using ChemiDoc and the software package Quantity One (both from Bio-Rad). Based on these values and the IP: 54.70.40.11
On: Sun, 13 Jan 2019 05:16:49 molecular masses of the marker proteins (His-X, 11 421 Da; His-P, 24 479 Da; His-N, 42 985 Da), the amount of virus-encoded protein, as well as the X : P : N ratio, was determined.
Immunofluorescence analysis. Immunofluorescence analysis was carried out as described previously (Geib et al., 2003) by applying the primary antibodies rabbit anti-N (Geib et al., 2003) , rabbit anti-P (Geib et al., 2003) and mAb 10/1G3, using a laser scanning microscope (Zeiss).
Peptide array analysis. Peptide arrays composed of overlapping 15mer fragments with an offset of 3 aa residues representing the protein sequences of X, P, N and M of strain He/80 (Pleschka et al., 2001) were chemically synthesized on cellulose sheets by the spotsynthesis technique as described previously (Frank, 1992) . Probing the arrays with antibodies was essentially carried out as described by Frank (1992) . Briefly, peptide arrays were blocked with membrane-blocking buffer overnight (Sigma-Genosys), followed by incubation with the corresponding antibody (1 : 1000 dilution) in blocking buffer for 3?5 h at room temperature. After three washes with Tris-buffered saline containing 0?05 % Tween 20, the peptidebound antibodies were detected by species-specific alkaline phosphatase-conjugated IgG antibodies, which were visualized by the blue-coloured precipitate formed from the BCIP/MTT substrate as described previously (Frank, 1992) . Signal patterns on the membranes were subsequently scanned for documentation.
Virus stock preparation and titration. Virus stocks were prepared from Oligo cells persistently infected with BDV strain He/80 as described previously (Briese et al., 1992) , titrated on Vero cells (Hallensleben et al., 1998) and concentrated by two steps of ultracentrifugation at 100 000 g for 1 h.
RESULTS AND DISCUSSION
mAb 10/1G3 recognizes a linear epitope of BDV X To detect X in BDV-infected cells we generated a mAb, designated 10/1G3, directed against this protein. In a peptide array analysis, the antibody recognized three neighbouring peptide spots corresponding to a linear epitope in the C terminus of X ( 70 PLHDLRPRP 78 ; Fig. 1a, left panel) . mAb 10/1G3 did not react with N, P or M (Fig. 1a, left  panel) . A cocktail of mAb 10/1G3, monospecific antibodies directed against N and P (Geib et al., 2003) and a peptidespecific antibody directed against M verified the integrity of these peptide arrays (Fig. 1a, right panel) .
In a Western blot analysis using total cell extract of Oligo cells persistently infected with BDV strain He/80 (Pleschka et al., 2001) , mAb 10/1G3 recognized a major band with a molecular mass of~16 kDa, whereas no signal was observed in cell extract from uninfected Oligo cells (Fig. 1b,  lanes 1 and 2) . Although the calculated molecular mass of X is only 9433 Da (Pleschka et al., 2001) , this band at 16 kDa most likely represents the X protein. BDV X is known to migrate slower in denaturing SDS-PAGE (Wehner et al., 1997; Kobayashi et al., 2003) . Furthermore, mAb 10/1G3 recognized a 16 kDa protein after transient expression of X in 293T cells (data not shown). This atypical migration is independent of the phosphorylation status of X, since E. coli-purified His-tagged X, with a molecular mass of 11 421 Da, migrated at approximately 17 kDa (see Fig. 3a ). The monospecific antibodies directed against N and P specifically recognized their corresponding antigens of the expected sizes (Fig. 1b) . These results demonstrated that mAb 10/1G3 specifically recognized X in virus-infected cells by binding to a linear epitope of this protein.
X co-localizes with N and P in the nucleus of BDV-infected Oligo cells
We next analysed the subcellular localization of X, P and N in BDV-infected cells by confocal microscopy using mAb 10/1G3 and the above-mentioned monospecific antibodies directed against N and P. All three antibodies identified BDV antigen in the nucleus as well as in the cytoplasm (Fig. 2a, left panels) . No specific signals were observed in uninfected cells (Fig. 2a , right panels). The nuclear punctuate staining of X was clearly visible in almost all infected cells and was similar to the signals observed with N and P, suggesting that these proteins co-localize in the nucleus. Double immunofluorescence analysis confirmed a colocalization of X with N ( Fig. 2b , upper panel) and X with P (Fig. 2b , lower panel) in the nucleus, as well as in the cytoplasm. These findings are in line with previous observations that X co-localizes with P and N in C6 cells persistently infected with BDV (Schwemmle et al., 1998) . Others, however, have observed a cytoplasmic accumulation of X and P in BDV-infected MDCK cells using a polyclonal X antiserum (Kobayashi et al., 2003) . The reason for this discrepancy is unclear, but may reflect differences in the nature of the antibodies used in these studies.
Levels of X protein in BDV-infected cells and virus stocks
To quantify the levels of X, P and N protein in persistently BDV-infected Oligo cells or virus stocks, we performed Western blot analysis using known quantities of E. colipurified His-tagged X (His-X), P (His-P) and N (His-N) as protein standards. Detection limits were found to be approximately 600 pg His-X for mAb 10/1G3 (Fig. 3a) , 40 pg His-P for antibody against P and 171 pg His-N for antibody against N (data not shown). Approximately 5 ng X could be detected in total extracts of infected cells, the equivalent of about 2610 5 cells (Fig. 3b) . Due to the high abundance of N and P in this cell extract, 100-fold fewer cells (2610 3 ) were used to facilitate quantification. By comparison with protein standards, these analyses revealed 600 pg P (Fig. 3c ) and 7 ng N (both isoforms together; Fig. 3d ), resulting in a relative molecular ratio of X : P : N in infected cells of 1 : 6 : 40. Using BDV virus stock corresponding to 2?56610 3 focus-forming units (f.f.u.), we failed to detect X (Fig. 3b) , whereas N and P could readily be detected (Fig. 3d) . However, threshold levels of X were detectable in virus stock samples corresponding to 2?56610 5 f.f.u. (Fig. 4) and were estimated to represent ¡600 pg X protein. Thus, the calculated relative molecular ratio of X : P : N in BDV virus stock was ¡1 : 330 : 1130. Based on this ratio, the length of the BDV genome of 9810 nt (Pleschka et al., 2001 ) and the assumption that The cellular localization of X, P and N in BDV-infected (Oligo/BDV) and uninfected Oligo cells (Oligo) was analysed by immunofluorescence using mAb 10/1G3 recognizing X (upper panels) and rabbit polyclonal antibodies recognizing either P (middle panels) or N (lower panels).
(b) Double immunofluorescence analysis of the subcellular localization of X and N (upper panels) and X and P (lower panels).
Note that X co-localizes with N and P in the nucleus as well as in the cytoplasm.
nucleoproteins of non-segmented, negative-strand RNA viruses cover on average 6-9 nt of the viral genome (Bhella et al., 2002; Calain & Roux, 1993; Thomas et al., 1985) , we estimated that approximately 1-1?5 molecules of the X protein were present in one BDV virus particle. However, we could not exclude the possibility that the threshold levels of X detected in BDV virus stock reflected contamination with cell extract due to the preparation procedure.
To study the expression of X during acute infection, we challenged Vero cells with BDV strain He/80 (0?1 f.f.u. per cell) and analysed the appearance and localization of this protein by immunofluorescence assay at 3, 4 and 5 days p.i. As judged by immunofluorescence assay, using the Pspecific serum, approximately 10 % of the cells were infected with BDV at 3 days p.i. and the infection increased slightly to 12 % by 5 days p.i. (data not shown). By 3 days p.i., X was clearly detectable in the nucleus of the infected cells, co-localizing with P (Fig. 5a, upper panels) . A similar colocalization of X and P was found in Vero cells persistently infected with BDV strain He/80 (Fig. 5a, lower panels) . Despite the presence of X during acute infection, the level of this protein at 3, 4 and 5 days p.i. was too low to be detected by mAb 10/1G3 in Western blot analysis using a cell extract corresponding to 2610 5 cells (Fig. 5b, upper  panel) , whereas approximately 10 ng X could readily be detected using a cell extract from Vero cells persistently infected with BDV (Fig. 5b, upper panel) . As expected from the low infection rate, the level of P in cell extract from acutely infected cells was significantly lower than in persistently infected cells (Fig. 5b, lower panel) . These results The amount of P was determined as described in (b), using cell extract from 2610 3 BDV-infected Oligo cells, virus stock corresponding to 320 f.f.u., the indicated amounts of E. coli-purified His-tagged P and a rabbit polyclonal antiserum recognizing P. (d) The amount of N was determined as described in (b) using cell extract from 2610 3 BDV-infected Oligo cells, virus stock corresponding to 320 f.f.u., the indicated amounts of E. coli-purified His-tagged N (2-fold dilution steps) and a rabbit polyclonal antibody recognizing N.
indicated that both X and P are expressed during acute infection, albeit at lower levels.
The extremely low level of X found in virus stocks indicates that this protein is incorporated at very low levels, if at all, into virus particles and therefore represents a non-structural protein of BDV. Exclusion of X from virus particles might allow efficient replication/transcription of the viral genome early in infection and is compatible with previous results showing that X-expressing cells are resistant to infection with BDV (Geib et al., 2003) . Later in the course of infection, the regulatory function of X might help to achieve and maintain viral persistence, e.g. by avoiding cell damage through extensive BDV replication.
The co-localization of X, P and N in the nucleus of infected cells does not support the hypothesis that X causes a cytoplasmic retention of P (Kobayashi et al., 2003; Poenisch et al., 2004) . Although there is no experimental evidence, an association of X with N-P complexes could explain colocalization of these proteins in the nucleus of BDV-infected Oligo cells. The non-overlapping X-and N-binding sites of P Schwemmle et al., 1998) may allow the simultaneous interaction with N and X. Alternatively, X may associate with RNP-bound P and thus block the polymerase activity. This is in line with the observation that P multimers can bind to L and X . However, this interaction might only be transient and X may be actively stripped from RNPs prior to packaging. Recently its was shown that the polymerase activity was restored in the presence of X by co-expression of G and M (Perez & de la Torre, 2005) . Thus, G and M might also prevent efficient packaging of X into viral particles. expression of Borna disease virus nucleocapsid components. J Virol 77, 4283-4290. 
